Brief: Salarius Pharmaceuticals Adds Two Mayo Clinic Sites To Its Ongoing Phase 1/2 Trial Of Seclidemstat As Treatment For Ewing's Sarcoma And FET-Rearranged Sarcomas

Decoy Therapeutics

22/08/2022 13:38

Aug 22 (Reuters) - Salarius Pharmaceuticals Inc  SLRX.O :
    * SALARIUS PHARMACEUTICALS ADDS TWO MAYO CLINIC SITES TO ITS
ONGOING PHASE 1/2 TRIAL OF SECLIDEMSTAT AS A TREATMENT FOR
EWING’S SARCOMA AND FET-REARRANGED SARCOMAS

Source text for Eikon:  ID:nGNX8S0gN2 
Further company coverage:  SLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))